SHEA

Original Article

Multiplexed gastrointestinal PCR panels for the evaluation of diarrhea in patients with acute leukemia

Clyde D. Ford MD[1] , Bert K. Lopansri MD[2,3], Bradley D. Hunter MD[1] , Jacob Wilkes BS[4] , Julie Asch MD[1] and Daanish Hoda MD[1]

[1]Intermountain Acute Leukemia Program, LDS Hospital, Salt Lake City, UT, USA, [2]Department of Medicine, Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, UT, USA, [3]Department of Medicine, Division of Infectious Diseases, University of Utah, Salt Lake City, UT, USA and [4]Data Analytics, Intermountain Health, Salt Lake City, UT, USA

Abstract

Objective: To better delineate multiplexed gastrointestinal polymerase chain reaction (PCR) panel (MGPP) diagnostic and therapeutic stewardship for patients undergoing treatment for acute leukemia including indications and benefits of testing, optimal timing, and interpretation of results.

Study design: We retrieved all MGPP ordered on 662 consecutive patients admitted with newly diagnosed acute leukemia between June 2015 and May 2024.

Setting: Regional referral center for acute leukemia.

Results: Fifty-one (17%) of 305 MGPP obtained on the 198 patients who underwent testing identified at least one and 4 (1%) more than one diarrheagenic pathogen. The probability of a positive result was greater if obtained as an outpatient [20/52(38%)], but was not related to type of leukemia, sex, or age. Among the positive results, the pathogens identified included *Clostridioides difficile* (78% of tests), norovirus (16%), diarrheagenic *Escherichia coli* (6%), adenovirus 40/41 (4%), and *Giardia lamblia* (4%). The results of 30 of the 305 tests resulted in a change in treatment (28 *C. difficile*, 2 *G. lamblia*). For the MGPP *C. difficile* results with an accompanying toxin determination, this included treatment following 16/19 tests with a positive toxin result and 11/19 with a negative. Actionable results other than *C. difficile* were rarely seen in the inpatient population.

Conclusions: MGPP testing is most useful when administered as an outpatient and of little benefit for inpatients with hospital-onset diarrhea. Since MGPP is sensitive and does not distinguish between colonization and causes of diarrhea, caution is needed in interpretation of results, especially for toxin-negative *C. difficile*.

Introduction

Multiplexed gastrointestinal polymerase chain reaction (PCR) panels (MGPP) are frequently employed as an aid in diarrhea management in various patient populations because of their ability to simultaneously determine the presence or absence in stool samples of the DNA from multiple bacteria, viruses, and protozoa with pathogenic potential. MGPP use has been touted as resulting in more rapid results, faster treatment, and lower costs.[1–3]

Diarrhea is a frequent complication in patients with acute leukemia undergoing therapy and may result from multiple potential causes including acute infections, antibiotic microbiome disruption, anti-neoplastic agent toxicity, supportive drug side effects, etc. In this vulnerable immunosuppressed population correctly diagnosing a diarrhea etiology is central to advantageous management and optimal outcomes. Especially important to

identify or eliminate are symptomatic and treatable infectious etiologies, potentially making MGPP an attractive option in these patients.

There are insufficient currently available data addressing the value of and optimal use of MGPP in patients with acute leukemia, and many unresolved questions remain about MGPP diagnostic stewardship in this cohort. In this large single-institution retrospective study, we review our experience with MGPP and discuss how our results might contribute to an improved understanding of MGPP optimal utilization in patients with acute leukemia.

Methods

Patients and procedures

The Intermountain Acute Leukemia Program (IALP) at LDS Hospital in Salt Lake City, Utah includes a 30-bed inpatient unit dedicated to the care of patients with hematologic malignancies, bone marrow failure syndromes, hematopoietic stem-cell transplant (HCT) recipients, and patients requiring other cellular therapies. Patients are housed in individual rooms with high-

efficiency particulate air filtration and positive-pressure airflow, have central venous catheters placed, and receive prophylactic proton pump inhibitors. In the absence of an indication for alternatives, all neutropenic patients with acute leukemia receive antibacterial prophylaxis with levofloxacin and antifungal prophylaxis with micafungin. Prior to May 2018, prophylactic penicillin was also administered with levofloxacin. In some patients, principally those experiencing prolonged neutropenic periods or steroid-containing regimens, *Pneumocystis jirovecii* prophylaxis with trimethoprim/sulfamethoxazole may be added. Empirical treatment for febrile neutropenia is either cefepime or piperacillin/tazobactam (PTZ), the choice alternated monthly. This was a quality improvement project of the Intermountain Acute Leukemia Program.

Multiplexed gastrointestinal PCR panels and Clostridioides difficile antigen and toxin testing

During the study period, a stool submitted to the clinical laboratory for *C. difficile* detection underwent testing for glutamate dehydrogenase (GDH) and *C. difficile* Toxin (CDIFF QUIK CHECK COMPLETE, TechLab, Blacksburg, VA). All GDH-positive/toxin-negative samples were assessed for the presence of toxin genes by PCR using Cepheid Xpert *C. difficile* PCR/EPI (Cepheid, Sunnyvale, CA) unless a concomitant MGPP was ordered, in which case the latter result was substituted. In September 2018 we introduced a new program guideline for submission of GDH/toxin testing and diagnosis/treatment of *C. difficile* infections, all of which were recently shown to have significantly decreased following guideline initiation in our stem-cell transplant recipients.[4]

Beginning in June 2015, the 22-pathogen BioFire FilmArray® Gastrointestinal Panel (BFA) has been in use at our institution. We retrieved all BFA performed on 662 consecutive patients referred to IALP for a new diagnosis of acute leukemia between June 2015 and May 2024. BFA results following administration of chimeric antigen receptor T-cell therapy or initiation of a preparative regimen for hematopoietic stem-cell transplantation were excluded.

Patient data

Clinical stool testing results were obtained from the Intermountain Health Enterprise Data Warehouse. Other clinical patient data were acquired from our program's clinical databases.

Definitions

A MGPP on admission was defined as one ordered on the day of or within 48 hrs. following admission. Testing requested >48 hours after admission was considered to be for evaluation of hospital-onset diarrhea. Testing <48 hours after admission and in clinics was considered to be for evaluation of community onset diarrhea.

Statistical analyses

Groups were compared using a 2-tailed Fisher's exact test or Mann-Whitney test. A *P* value ≤ 0.05 was considered significant.

Results

Patient characteristics for the 662 patients are shown in Table 1. The myeloid predominance and patient demographics are as expected for this relatively unselected adult community

Table 1. Characteristics of the 662 patients with acute leukemia

Age median (range), Yr	63 (18–90)
Female sex	300
Leukemia Subtype	
Myelogenous	503
Lymphocytic	122
Multi-lineage	9
CML Blast Crisis	24
Undifferentiated	2
T-cell Leukemia/Lymphoma	2
Anti-leukemia therapy	607
Proceeded to transplant	132

CML, chronic myelogenous leukemia.

population. Fifty-five patients received no anti-leukemic therapy because of patient choice and/or clinical unsuitability. During the study period the 662 patients underwent 1888 total hospital admissions, and 198 of the patients underwent 305 BFA determinations.

Prevalence and results of testing for infectious diarrhea

Diarrhea was a frequent complication in our 662-patient cohort, especially diarrhea without an identified infectious etiology. During the study period 352 (53%) of the patients had undergone testing (BFA and/or *C. difficile* antigen/toxin) with 101 (29%) patients showing any positive result during their treatment course. Of the total tests submitted 136/856 (16%) were positive.

Positivity of BFA testing

Fifty-one (17%) of the 305 requested tests were positive. These included 43 patients, 8 of whom had 2 positive tests each (Table S1). In 4 of the positive tests (8%) *C. difficile* was identified in association with a second pathogen (Table S2).

A BFA test was more likely to be positive when obtained for evaluation of diarrhea in an outpatient setting [20/52(38%)] as compared with hospital-onset diarrhea [17/191(9%); *P* <0.0001)], but not when diarrhea was present at hospital admission [14/62(23%); *P* = 0.1)] (Table 2). The probability of a positive requested BFA test was not statistically significantly related to the patient's type of leukemia (AML vs. other), sex, or age.

BFA pathogens identified

The pathogens identified at various stages of acute leukemia treatment are summarized in Table 2 and by year in Table S3. Of the 22 potential pathogens evaluated in the 51 positive results, those detected included *C. difficile* [40/51 (78%)], norovirus [8/51 (16%)], enteropathogenic *Escherichia coli* (EPEC) [2/51 (4%)], adenovirus 40/41 [2/51 (4%)], *Giardia lamblia* [2/51 (4%)], and enterotoxigenic *Escherichia coli* (ETEC) [1/51 (2%)]. Three patients had a positive and a negative test within 14 days of each other; the pathogens identified included *C. difficile*, *C. difficile*, and norovirus.

Table 2. Pathogens identified by BioFire FilmArray® for evaluation of diarrhea

	Initial Hospitalization		Subsequent hospitalizations		
Number patients	Admission	Hospital onset	Admission	Hospital Onset	Outpatient
Number patients	17	109	20	18	32
Number tests	17	144	45	47	52
Number Pos	2	8	12	9	20
Organisms					
C. difficile	1	8	8	9	14
EPEC		1			1
ETEC					1
Adenovirus 40/41				1	1
Norovirus			4		4
Giardia lamblia	1				1

EPEC, Enteropathogenic *Escherichia coli;* ETEC, Enterotoxigenic *Escherichia coli.*

BFA results and changes in patient management

Thirty (59% of the positive and 10% of all submitted tests) positive BFA tests resulted in the initiation of treatment. These included 28/40 (70%) with *C. difficile* and 2/2 with *Giardia lamblia.*

The predominance of C. difficile

For our cohort undergoing BFA, predominance of *C. difficile* among positive stool results was apparent for all subgroups in Table 2. Only 15/305 (5%) of the total tests and 7/253 (3%) of the inpatient tests identified a pathogen other than *C. difficile*; with only the two *Giardia lamblia* results actionable. Of the 40 total BFA tests that identified *C. difficile*, 38 included concomitant testing for the presence of *C. difficile* toxin and 19 of these were positive. *C. difficile* therapy was administered to 16/19 (84%) toxin-positive and 11/19 (58%) toxin-negative patients. Notably, all but 2 of the BFA tests detecting pathogens other than *C. difficile* had been ordered at admission or as an outpatient, reflecting likely community acquisition (Table 2).

Discussion

Diarrhea is frequently encountered in patients undergoing therapy for acute leukemia and expeditiously arriving at a diagnosis and initiating treatment, when necessary, may significantly contribute to maximizing desired outcomes and minimizing costs. As in our program, MGPP is likely frequently employed at other institutions in the investigation of leukemia-associated diarrhea, resulting in increased odds of identifying a potentially pathologic organism. However, the clinical significance of these identifications is not always clear, and there is a need for better definitions of the judicious use of MGPP in these patients.

Our data show that the most efficient use of MGPP in patients undergoing therapy for acute leukemia is in the evaluation of outpatient diarrhea. This is not surprising as a new diarrhea in these instances is more likely to be due to community acquired pathogens, and all targets in the MGPP except for *C. difficile* are most commonly acquired in the community setting. Conversely, hospitalized patients would be expected to more frequently have diarrhea caused by the multiple potential noninfectious etiologies seen in the acute leukemia population. In addition, the lack of actionable diarrheagenic organisms other than *C. difficile* (with the rare exception of *Giardia lamblia*) identified in our cohort with admission and hospital-onset diarrheas suggests that testing for *C. difficile*, perhaps including an assay for *C. difficile* toxin, may be the more efficient approach in these situations.

A potentially significant problem with the use of PCR methodologies is overdiagnosis and overtreatment. Although detecting more potential pathogens because of greater analytic sensitivity, such tests do not distinguish between non-viable forms, colonization, and clinically insignificant infections, and can lead to delays in identifying the actual etiology of the diarrhea. In patient populations such as our leukemia cohort, a higher prevalence of noninfectious diarrhea, especially in the inpatient setting, combined with increased colonization rates may contribute to a significant lowering of MGPP testing specificity.

The problem of overdiagnosis is especially concerning for *C. difficile*, the most frequently and consistently identified organism in MGPP testing. Our data show that diarrhea is common in patients undergoing therapy for acute leukemia with the majority of instances due to causes other than *C. difficile* infection. Also, we have previously reported a *C. difficile* colonization rate at admission of 13% in our acute leukemic population.[5] The risk for overdiagnosis may be greater when the PCR positivity is accompanied by a negative toxin assay. Prior studies in large general inpatient populations have shown that only toxin-positive stools are associated with significant morbidity and mortality and that reliance on molecular testing alone may lead to overdiagnosis and overtreatment.[6–8] Similar results may apply to our acute leukemia cohort, although more information is needed. It was with these challenges in mind that our new guidelines for *C. difficile* diagnostic and antibiotic stewardship were adopted in our unit in 2018.[4]

Similar issues of overdiagnosis/treatment are encountered with the detection of diarrheagenic *E. coli* species, which are commonly reported in MGPP series.[1–3,9,10] These seemed to be less common in our acute leukemia cohort and our hematopoietic stem-cell transplant patients, which is not surprising as many of these targets (EPEC, EAEC, ETEC) are less common causes of gastroenteritis in the United States. In addition, the lack of reproducibility for certain MGPP rare targets[12] and the inability

to confirm the presence of EPEC, EAEC, and ETEC may create other challenges in a cohort of patients such as our leukemia population with numerous potential causes of diarrhea, especially since these targets are not infrequently detected with other targets. These observations point to important questions for future study such as how to establish the clinical significance, need for treatment, and impact of colonization of these organisms in the acute leukemia population.

Limitations of our study include a retrospective design, a single institution experience that may reflect local practice preferences and dependence on chart reviews for clinical data. Given the long duration of the study data, it is likely that changes in policies during the interval, such as introduction of the *C. difficile* guideline, may have affected clinician ordering and treatment patterns.

In summary, we conclude that when used to evaluate for an infectious cause of diarrhea in patients with acute leukemia, BFA is most useful in the outpatient setting. For hospital-acquired diarrhea, targeted testing for *C. difficile* toxin is a more efficient, cost-effective approach, and routine testing with MGPP, which consists mostly of pathogens that are transmitted in the community, is not warranted. The clinical significance of diarrheagenic *E. coli*, other than STEC, and MGPP rare targets needs further evaluation.

References

1. Cybulski RJ, Bateman AC, Bourassa L, *et al.* Clinical impact of a multiplex gastrointestinal polymerase chain reaction panel in patients with acute gastroenteritis. *Clin Infect Dis* 2018;67:1688–1696.
2. Beal SG, Tremblay EE, Toffel S, Velez L, Rand KH. A gastrointestinal PCR panel improves clinical management and lowers health care costs. *J Clin Microbiol* 2018;56:e01457–17.
3. Axelrad JE, Freedberg DE, Whittier S, Greendyke W, Lebwohl B, Green DA. Impact of gastrointestinal panel implementation on health care utilization and outcomes. *J Clin Microbiol* 2019;57:e01775–18.
4. Ford CD, Hoda D, Lopansri BK, Parra M, Sharma P, Asch J. An algorithm addressing the problem of overdiagnosis of *Clostridioides difficile* infections in hematopoietic stem cell transplantation recipients: effects on *C. difficile* infection rates and patient outcomes. *Transplant Cell Ther* 2023;29:471.e1–471.e7.
5. Ford CD, Lopansri BK, Webb BR, *et al.* *Clostridioides difficile* colonization and infection in patients with newly diagnosed acute leukemia: incidence, risk factors, and patient outcomes. *Am J Infect Control* 2019;47:394–399.
6. Planche TD, Davies KA, Coen PG, *et al.* Differences in outcome according to *Clostridium difficile* testing method: a prospective multicenter diagnostic validation study of *C. difficile* infection. *Lancet* 2013;13:936–945.
7. Baker I, Leeming JP, Reynolds R, Ibrahim I; Darley E. Clinical relevance of a positive molecular test in the diagnosis of *Clostridium difficile* infection. *J Hosp Infect* 2013;84:311–315.
8. Polage CR, Gyorke CE, Kennedy MA, *et al.* Overdiagnosis of *Clostridium difficile* infection in the molecular test era. *JAMA Intern Med* 2015;175: 1792–1801.
9. Khare R, Espy MJ, Cebelinshi E, *et al.* Comparative evaluation of two commercial multiplex panels for detection of gastrointestinal pathogens by use of clinical stool specimens. *J Clin Microbiol* 2014;52:3667–3673.
10. Spina A, Kerr KG, Cermican M, *et al.* Spectrum of enteropathogens detected for the FilmArray GI Panel in a multicentre study of community-acquired gastroenteritis. *Clin Microbiol Infect* 2015;21:719–728.
11. Ford CD, Lopansri BK, Hunter BD, Asch J, Hoda D. Multiplexed gastrointestinal PCR panels for the evaluation of diarrhea in hematopoietic stem cell transplantation recipients. *Transplant Cell Ther* 2024;30: 814.e1–814.e7.
12. Hitchcock MM, Hogan CA, Budvitiene I, Banaei N. Reproducibility of positive results for rare pathogens on the FilmArray GI panel. *Diagn Microbiol Infect Dis* 2019;95:10–14.